• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA warns about non-invasive prenatal screening tests

FDA warns about non-invasive prenatal screening tests

April 20, 2022 By Sean Whooley

FDAThe FDA issued a warning about the risk of false results, inappropriate use and inappropriate result interpretation with prenatal tests.

Non-invasive prenatal screening (NIPS) tests, also known as cell-free DNA tests or non-invasive prenatal tests (NIPT) look for signs of genetic abnormalities in a fetus by testing a sample of blood from the pregnant person.

According to an FDA release, NIPS tests can provide information about the possibility that a child will be born with a serious health condition, but they are screening tests, not diagnostics, meaning they only provide information about the risk that a fetus may have a genetic abnormality. Additional testing may be needed to confirm whether a fetus is affected.

All NIPS tests on the market are offered as laboratory-developed tests (LDTs) and most LDTs, including NIPS tests, are offered without FDA review. The FDA said it continues to work with Congress on legislation to establish a modern regulatory framework for all tests, including LDTs, as the agency does not generally enforce applicable regulatory requirements for most of them.

The FDA said that it is concerned with claims of laboratories offering the tests as “reliable” and “highly accurate” while providing “peace of mind for patients.” The agency said these claims may not be supported with sound scientific evidence.

Patients and healthcare providers are warned of risks and limitations with using NIPS tests, as the FDA is aware of reports that they have made critical healthcare decisions based on results of the screening tests without additional confirmatory diagnostic testing, meaning patients have ended pregnancies based on results of the screening without understanding the limitations.

The FDA recommends that patients and providers discuss benefits and risks of such testing with a genetic counselor or other healthcare providers before considering such testing or making decisions on the pregnancy.

“While genetic non-invasive prenatal screening tests are widely used today, these tests have not been reviewed by the FDA and may be making claims about their performance and use that are not based on sound science,” FDA Center for Devices and Radiological Health Director Dr. Jeff Shuren said in the release. “Without proper understanding of how these tests should be used, people may make inappropriate health care decisions regarding their pregnancy. We strongly urge patients to discuss the benefits and risks of these tests with a genetic counselor or other health care provider prior to making decisions based on the results of these tests.”

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: FDA

More recent news

  • FDA adds Gradient denervation tech to advisory program
  • Former Intuitive sales leader joins surgical robot maker Virtual Incision as CEO
  • Smith+Nephew to open first orthopedic ambulatory surgery center in the UK
  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy